Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.





Inbox: Valneva: OK von der EU-Kommission für mind. 60 Mio. Dosen vom Covid-Impfstoff VLA2001 ist da


Saint-Herblain (France), November 10, 2021Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Commission (“EC”) has approved an agreement pursuant to which Valneva would supply up to 60 million doses of VLA2001, its inactivated COVID-19 vaccine candidate, over two years including approximately 27 million doses in 2022.

Under the current terms of the agreement, the EC has the option to increase its initial purchase, in 2022, of VLA2001 up to a total of 60 million doses by the end of 2023. The agreement will be completed following final review, including volumes required, by each of the European Union Member States. Today’s announcement follows the conclusion of advanced exploratory talks with the European Commission that began in January 2021. Delivery of the vaccine is currently expected to begin in April 2022, subject to approval by the European Medicines Agency (EMA) human medicines committee (CHMP), which is expected to start a rolling review of VLA2001 shortly.

Thomas Lingelbach, Chief Executive Officer of Valneva, said, “We are grateful to the European Commission for its support and are eager to help address the ongoing pandemic. We continue to receive messages from people across the world who are waiting for an inactivated vaccine. We are deeply committed to bringing an alternative vaccine solution to the market as quickly as possible and continue to work tirelessly to achieve that. Our Phase 3 results confirmed the advantages often associated with inactivated vaccines and we continue to believe that our differentiated vaccine candidate could make an important contribution to the global fight against the COVID-19 pandemic.”

Franck Grimaud, Chief Business Officer of Valneva, commented, “I would like to express my thanks to the respective teams in the EC and across Valneva who have worked assiduously on this agreement. We are looking forward to completing the agreement and getting the rolling review with EMA underway. Our recent Phase 3 data have allowed us to showcase the value of VLA2001 and we believe that other supply deals could follow this one.”

Valneva reported positive Phase 3 results for VLA2001 in October 2021[1]. VLA2001 demonstrated superiority in terms of neutralizing antibody titer levels against the active comparator vaccine, AstraZeneca’s AZD1222, as well as non-inferiority in terms of seroconversion rates and a significantly better tolerability profile.

About VLA2001

VLA2001 is currently the only whole virus, inactivated, adjuvanted vaccine candidate against COVID-19 in clinical trials in Europe. It is intended for active immunization of at-risk populations to prevent carriage and symptomatic infection with COVID-19 during the ongoing pandemic and potentially later for routine vaccination including addressing new variants. VLA2001 may also be suited for boosting, as repeat booster vaccinations have been shown to work well with whole virus inactivated vaccines. VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging the manufacturing technology for Valneva’s licensed Japanese encephalitis vaccine, IXIARO®. VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018. This adjuvant combination has consistently induced higher antibody levels in preclinical experiments than alum-only formulations and shown a shift of the immune response towards Th1. CpG 1018 adjuvant, supplied by Dynavax Technologies Corporation (Nasdaq: DVAX), is a component of the US FDA- and EMA-approved HEPLISAV-B®  vaccine. The manufacturing process for VLA2001, which has already been upscaled to final industrial scale, includes chemical inactivation to preserve the native structure of the S-protein. VLA2001 is expected to conform with standard cold chain requirements (2 degrees to 8 degrees Celsius).

About Valneva SE

Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.


Valneva startet an der Nasdaq, Fotoquelle: Screenshot von Nasdaq.com © Aussender



Aktien auf dem Radar:Rosenbauer, Frequentis, SBO, Austriacard Holdings AG, Addiko Bank, RHI Magnesita, EVN, VIG, Wienerberger, Pierer Mobility, Bawag, UBM, SW Umwelttechnik, Oberbank AG Stamm, Agrana, Amag, CA Immo, Erste Group, Flughafen Wien, Immofinanz, Kapsch TrafficCom, Palfinger, Österreichische Post, Telekom Austria, Uniqa, Covestro, Deutsche Telekom, Intel, JP Morgan Chase, Deutsche Boerse, Beiersdorf.

(BSN-Hinweis: Lauftext im Original des Aussenders, Titel (immer) und Bebilderung (oft) durch boerse-social.com aus dem Fotoarchiv von photaq.com)

Random Partner #goboersewien

VBV
Die VBV-Gruppe ist führend bei betrieblichen Vorsorgelösungen in Österreich. Sowohl im Bereich der Firmenpensionen als auch bei der Abfertigung NEU ist die VBV Marktführer. Neben der VBV-Pensionskasse und der VBV-Vorsorgekasse gehören auch Dienstleistungsunternehmen wie die VBV-Pensionsservice-Center, die VBV-Consult, die VBV-Asset Service und die Betriebliche Altersvorsorge-SoftWare Engineering zur VBV-Gruppe.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/goboersewien


Meistgelesen
>> mehr





PIR-Zeichnungsprodukte
AT0000A3AGF0
AT0000A2C5J0
AT0000A382G1
Newsflow
>> mehr

Börse Social Club Board
>> mehr
    Star der Stunde: Warimpex 3.78%, Rutsch der Stunde: Palfinger -2.67%
    wikifolio-Trades Austro-Aktien 9-10: Lenzing(3), ams-Osram(2), SBO(1), OMV(1), Wienerberger(1)
    Star der Stunde: Warimpex 3.78%, Rutsch der Stunde: Palfinger -2.67%
    wikifolio-Trades Austro-Aktien 8-9: Bawag(2), Frequentis(1)
    Himax zu Strabag
    BSN MA-Event Covestro
    BSN MA-Event Deutsche Telekom
    BSN MA-Event Flughafen Wien
    BSN MA-Event Flughafen Wien

    Featured Partner Video

    Wiener Börse Party #622: Daumen drücken für RBI und die Wiener Börse, die an die Börse sollte, AT&S, Bawag und VIG vor Marken

    Die Wiener Börse Party ist ein Podcastprojekt für Audio-CD.at von Christian Drastil Comm.. Unter dem Motto „Market & Me“ berichtet Christian Drastil über das Tagesgeschehen an der Wiener Börse....

    Books josefchladek.com

    Naotaka Hirota
    La Scène de la Locomotive à Vapeur
    1975
    Yomiuri Shimbun

    François Jonquet
    Forage
    2023
    Void

    Martin Frey & Philipp Graf
    Spurensuche 2023
    2023
    Self published

    Federico Renzaglia
    Bonifica
    2024
    Self published

    Cristina de Middel
    Gentlemen's Club
    2023
    This Book is True

    Inbox: Valneva: OK von der EU-Kommission für mind. 60 Mio. Dosen vom Covid-Impfstoff VLA2001 ist da


    10.11.2021, 4850 Zeichen

    Saint-Herblain (France), November 10, 2021Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Commission (“EC”) has approved an agreement pursuant to which Valneva would supply up to 60 million doses of VLA2001, its inactivated COVID-19 vaccine candidate, over two years including approximately 27 million doses in 2022.

    Under the current terms of the agreement, the EC has the option to increase its initial purchase, in 2022, of VLA2001 up to a total of 60 million doses by the end of 2023. The agreement will be completed following final review, including volumes required, by each of the European Union Member States. Today’s announcement follows the conclusion of advanced exploratory talks with the European Commission that began in January 2021. Delivery of the vaccine is currently expected to begin in April 2022, subject to approval by the European Medicines Agency (EMA) human medicines committee (CHMP), which is expected to start a rolling review of VLA2001 shortly.

    Thomas Lingelbach, Chief Executive Officer of Valneva, said, “We are grateful to the European Commission for its support and are eager to help address the ongoing pandemic. We continue to receive messages from people across the world who are waiting for an inactivated vaccine. We are deeply committed to bringing an alternative vaccine solution to the market as quickly as possible and continue to work tirelessly to achieve that. Our Phase 3 results confirmed the advantages often associated with inactivated vaccines and we continue to believe that our differentiated vaccine candidate could make an important contribution to the global fight against the COVID-19 pandemic.”

    Franck Grimaud, Chief Business Officer of Valneva, commented, “I would like to express my thanks to the respective teams in the EC and across Valneva who have worked assiduously on this agreement. We are looking forward to completing the agreement and getting the rolling review with EMA underway. Our recent Phase 3 data have allowed us to showcase the value of VLA2001 and we believe that other supply deals could follow this one.”

    Valneva reported positive Phase 3 results for VLA2001 in October 2021[1]. VLA2001 demonstrated superiority in terms of neutralizing antibody titer levels against the active comparator vaccine, AstraZeneca’s AZD1222, as well as non-inferiority in terms of seroconversion rates and a significantly better tolerability profile.

    About VLA2001

    VLA2001 is currently the only whole virus, inactivated, adjuvanted vaccine candidate against COVID-19 in clinical trials in Europe. It is intended for active immunization of at-risk populations to prevent carriage and symptomatic infection with COVID-19 during the ongoing pandemic and potentially later for routine vaccination including addressing new variants. VLA2001 may also be suited for boosting, as repeat booster vaccinations have been shown to work well with whole virus inactivated vaccines. VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging the manufacturing technology for Valneva’s licensed Japanese encephalitis vaccine, IXIARO®. VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018. This adjuvant combination has consistently induced higher antibody levels in preclinical experiments than alum-only formulations and shown a shift of the immune response towards Th1. CpG 1018 adjuvant, supplied by Dynavax Technologies Corporation (Nasdaq: DVAX), is a component of the US FDA- and EMA-approved HEPLISAV-B®  vaccine. The manufacturing process for VLA2001, which has already been upscaled to final industrial scale, includes chemical inactivation to preserve the native structure of the S-protein. VLA2001 is expected to conform with standard cold chain requirements (2 degrees to 8 degrees Celsius).

    About Valneva SE

    Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.


    Valneva startet an der Nasdaq, Fotoquelle: Screenshot von Nasdaq.com © Aussender




    Was noch interessant sein dürfte:


    Inbox: TTI-Group Jobbarometer: Viele Unternehmen haben den Ernst der Lage noch nicht erkannt

    Inbox: ESG-Investments: Wenn man Unternehmen plötzlich ausschliessen muss

    Inbox: Wachstumsmarkt Luxusgüter, Lederwaren besonders gefragt: Hermès und LVMH dominieren das Segment

    Inbox: Kathrein Privatbank: Inflation bleibt das heisse Thema

    Inbox: IVA: Ökosoziale Steuerreform bringt für Anleger bisher wenig

    Inbox: Warum Evergrande nicht in Konkurs gehen wird und was das für China-Aktien bedeutet (Kathrein)

    Inbox: Wemove Runningstore eröffnet am 3.3.2022 im Donauzentrum den größten Laufshop Österreichs

    Inbox: ICT Poland sorgt für den nächsten Andritz-Auftrag

    Audio: Alois Wögerbauer: "Ich glaube der Hauptgrund für die Korrektur war der Konflikt Russland-Ukraine"

    Inbox: Marinomed: Konvertierungsmeldung aus dem Funding Programm

    Inbox: OMV kündigt einen Bond

    Audio: Marinomed-CEO Andreas Grassauer: "Wir werden jedes Jahr im Winter eine Corona Welle haben"

    Inbox: Vorsicht: Aufsicht schaut verstärkt auf Anlageempfehlungen in sozialen Medien



    BSN Podcasts
    Christian Drastil: Wiener Börse Plausch

    Börsepeople im Podcast S12/06: Curt Chadha




     

    Bildnachweis

    1. Valneva startet an der Nasdaq, Fotoquelle: Screenshot von Nasdaq.com , (© Aussender)   >> Öffnen auf photaq.com

    Aktien auf dem Radar:Rosenbauer, Frequentis, SBO, Austriacard Holdings AG, Addiko Bank, RHI Magnesita, EVN, VIG, Wienerberger, Pierer Mobility, Bawag, UBM, SW Umwelttechnik, Oberbank AG Stamm, Agrana, Amag, CA Immo, Erste Group, Flughafen Wien, Immofinanz, Kapsch TrafficCom, Palfinger, Österreichische Post, Telekom Austria, Uniqa, Covestro, Deutsche Telekom, Intel, JP Morgan Chase, Deutsche Boerse, Beiersdorf.


    Random Partner

    VBV
    Die VBV-Gruppe ist führend bei betrieblichen Vorsorgelösungen in Österreich. Sowohl im Bereich der Firmenpensionen als auch bei der Abfertigung NEU ist die VBV Marktführer. Neben der VBV-Pensionskasse und der VBV-Vorsorgekasse gehören auch Dienstleistungsunternehmen wie die VBV-Pensionsservice-Center, die VBV-Consult, die VBV-Asset Service und die Betriebliche Altersvorsorge-SoftWare Engineering zur VBV-Gruppe.

    >> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


    Valneva startet an der Nasdaq, Fotoquelle: Screenshot von Nasdaq.com, (© Aussender)


    Useletter

    Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

    Newsletter abonnieren

    Runplugged

    Infos über neue Financial Literacy Audio Files für die Runplugged App
    (kostenfrei downloaden über http://runplugged.com/spreadit)

    per Newsletter erhalten


    Meistgelesen
    >> mehr





    PIR-Zeichnungsprodukte
    AT0000A3AGF0
    AT0000A2C5J0
    AT0000A382G1
    Newsflow
    >> mehr

    Börse Social Club Board
    >> mehr
      Star der Stunde: Warimpex 3.78%, Rutsch der Stunde: Palfinger -2.67%
      wikifolio-Trades Austro-Aktien 9-10: Lenzing(3), ams-Osram(2), SBO(1), OMV(1), Wienerberger(1)
      Star der Stunde: Warimpex 3.78%, Rutsch der Stunde: Palfinger -2.67%
      wikifolio-Trades Austro-Aktien 8-9: Bawag(2), Frequentis(1)
      Himax zu Strabag
      BSN MA-Event Covestro
      BSN MA-Event Deutsche Telekom
      BSN MA-Event Flughafen Wien
      BSN MA-Event Flughafen Wien

      Featured Partner Video

      Wiener Börse Party #622: Daumen drücken für RBI und die Wiener Börse, die an die Börse sollte, AT&S, Bawag und VIG vor Marken

      Die Wiener Börse Party ist ein Podcastprojekt für Audio-CD.at von Christian Drastil Comm.. Unter dem Motto „Market & Me“ berichtet Christian Drastil über das Tagesgeschehen an der Wiener Börse....

      Books josefchladek.com

      Stefania Rössl & Massimo Sordi (eds.)
      Index Naturae
      2023
      Skinnerboox

      Valie Export
      Körpersplitter
      1980
      Veralg Droschl

      Ros Boisier
      Inside
      2024
      Muga / Ediciones Posibles

      Federico Renzaglia
      Bonifica
      2024
      Self published

      Helen Levitt
      A Way of Seeing
      1965
      The Viking Press